Literature DB >> 12751040

Rhinovirus induction of the CXC chemokine epithelial-neutrophil activating peptide-78 in bronchial epithelium.

Howard Donninger1, Richard Glashoff, Hans-Michael Haitchi, James A Syce, Reena Ghildyal, Estrelita van Rensburg, Philip G Bardin.   

Abstract

Epithelial-neutrophil activating peptide-78 (ENA-78) induces neutrophil migration, an early response to viral infection. Rhinovirus serotype 16 (RV16) was used to infect primary bronchial epithelial cells and a cell line (BEAS-2B). Release of ENA-78 protein was measured by enzyme-linked immunosorbent assay, ENA-78 mRNA production was quantified by reverse-transcription polymerase chain reaction, and ENA-78 promoter activity was assessed by use of a promoter construct. After infection with RV16, ENA-78 protein and mRNA increased significantly, and RV16 induced 3-fold increases in ENA-78 gene transcription. Nasal ENA-78 measured in patients with asthma with and without RV infection was more elevated in patients with RV infection present. Our study demonstrates that ENA-78 is produced in bronchial epithelial cells in response to RV16 infection. With other chemokines, it may be an important initiator of neutrophil airway inflammation during RV common colds and thus may play a role in the development of virus-associated airway pathologies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751040     DOI: 10.1086/375246

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Cigarette smoke decreases innate responses of epithelial cells to rhinovirus infection.

Authors:  Jane Eddleston; Rachel U Lee; Astrid M Doerner; Jack Herschbach; Bruce L Zuraw
Journal:  Am J Respir Cell Mol Biol       Date:  2010-03-11       Impact factor: 6.914

2.  Effect of double-stranded RNA on the expression of epithelial neutrophil activating peptide-78/CXCL-5 in human endothelial cells.

Authors:  Tadaatsu Imaizumi; Masaharu Hatakeyama; Kageaki Taima; Akira Ishikawa; Koji Yamashita; Hidemi Yoshida; Kei Satoh
Journal:  Inflammation       Date:  2004-08       Impact factor: 4.092

3.  Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma.

Authors:  Yusheng Qiu; Jie Zhu; Venkata Bandi; Kay K Guntupalli; Peter K Jeffery
Journal:  Thorax       Date:  2007-01-18       Impact factor: 9.139

Review 4.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

5.  CXCR2 is required for neutrophilic airway inflammation and hyperresponsiveness in a mouse model of human rhinovirus infection.

Authors:  Deepti R Nagarkar; Qiong Wang; Jee Shim; Ying Zhao; Wan C Tsai; Nicholas W Lukacs; Uma Sajjan; Marc B Hershenson
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

6.  Response to rhinovirus infection by human airway epithelial cells and peripheral blood mononuclear cells in an in vitro two-chamber tissue culture system.

Authors:  Devi Rajan; Kelsey A Gaston; Courtney E McCracken; Dean D Erdman; Larry J Anderson
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

Review 7.  Challenge models to assess new therapies in chronic obstructive pulmonary disease.

Authors:  René van der Merwe; Nestor A Molfino
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-13

Review 8.  Rhinoviruses, allergic inflammation, and asthma.

Authors:  Monica L Gavala; Paul J Bertics; James E Gern
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

9.  Lower respiratory tract infection induced by a genetically modified picornavirus in its natural murine host.

Authors:  Louis A Rosenthal; Renee J Szakaly; Svetlana P Amineva; Yina Xing; Marchel R Hill; Ann C Palmenberg; James E Gern; Ronald L Sorkness
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

10.  A rat model of picornavirus-induced airway infection and inflammation.

Authors:  Louis A Rosenthal; Svetlana P Amineva; Renee J Szakaly; Robert F Lemanske; James E Gern; Ronald L Sorkness
Journal:  Virol J       Date:  2009-08-11       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.